Pharsight

Drug Patents Expiring in 2024

1. Abilify patents expiration

ABILIFY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(2 months from now)

US7550445 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(3 months from now)

US7115587 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(3 months from now)

US8017615

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Dec, 2024

(8 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 15 November, 2002

Treatment: Treatment of schizophrenia

Dosage: TABLET;ORAL

How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage

ABILIFY family patents

Family Patents

2. Abilify Maintena Kit patents expiration

ABILIFY MAINTENA KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722679 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(6 months from now)

US8030313 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(6 months from now)

US7807680 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(6 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Treatment of schizophrenia; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents

3. Abilify Mycite Kit patents expiration

ABILIFY MYCITE KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(2 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

4. Abraxane patents expiration

ABRAXANE's oppositions filed in EPO
ABRAXANE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7923536

(Pediatric)

BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Jun, 2024

(2 months from now)

US8314156

(Pediatric)

BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Jun, 2024

(2 months from now)

US8138229

(Pediatric)

BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Jun, 2024

(2 months from now)

US7820788 BRISTOL MYERS SQUIBB CO Compositions and methods of delivery of pharmacological agents
Oct, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity (PED) Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of lung cancer; Treatment of breast cancer; Treatment of pancreatic cancer

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage

ABRAXANE family patents

Family Patents

5. Acular Ls patents expiration

Can you believe ACULAR LS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216167 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US8946281 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US8648107 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US8377982 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US8541463 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US8207215 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US8906950 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(2 months from now)

US8207215

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(8 months from now)

US8541463

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(8 months from now)

US8377982

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(8 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: A method of treating ocular pain and/or enhancing ocular comfort; A method of treating ocular pain; A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A met...

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACULAR LS before it's drug patent expiration?
More Information on Dosage

ACULAR LS family patents

Family Patents

6. Acuvail patents expiration

ACUVAIL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same
Aug, 2024

(4 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 22 July, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACUVAIL before it's drug patent expiration?
More Information on Dosage

ACUVAIL family patents

Family Patents

7. Adasuve patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9370629 ALEXZA PHARMS Self-contained heating unit and drug-supply unit employing same
May, 2024

(a month from now)

US8991387 ALEXZA PHARMS Self-contained heating unit and drug-supply unit employing same
May, 2024

(a month from now)

US7458374 ALEXZA PHARMS Method and apparatus for vaporizing a compound
Aug, 2024

(4 months from now)

US7537009 ALEXZA PHARMS Method of forming an aerosol for inhalation delivery
Oct, 2024

(7 months from now)

Drugs and Companies using LOXAPINE ingredient

Market Authorisation Date: 21 December, 2012

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ADASUVE family patents

Family Patents

8. Airduo Digihaler patents expiration

AIRDUO DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024 TEVA PHARM Process for preparing a medicament
Sep, 2024

(5 months from now)

US9987229 TEVA PHARM Process for preparing a medicament
Sep, 2024

(5 months from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

9. Aldara patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7696159 BAUSCH Treatment for basal cell carcinoma
Apr, 2024

(6 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696159

(Pediatric)

BAUSCH Treatment for basal cell carcinoma
Oct, 2024

(6 months from now)

Drugs and Companies using IMIQUIMOD ingredient

Market Authorisation Date: 27 February, 1997

Treatment: Treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); Works through the induction of interferon and other cytokines

Dosage: CREAM;TOPICAL

How can I launch a generic of ALDARA before it's drug patent expiration?
More Information on Dosage

ALDARA family patents

Family Patents

10. Aliqopa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7511041 BAYER HEALTHCARE Fused azole-pyrimidine derivatives
May, 2024

(a month from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 14, 2024

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

Market Authorisation Date: 14 September, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ALIQOPA family patents

Family Patents

11. Aloxi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9125905

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(4 months from now)

US9173942

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(4 months from now)

US8598219

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(4 months from now)

US9457021

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(4 months from now)

US7947724

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(4 months from now)

US7947725

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(4 months from now)

US7960424

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(4 months from now)

US8518981

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(4 months from now)

US8598218

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(4 months from now)

US8729094

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(4 months from now)

US9457020

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(4 months from now)

US9066980

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(4 months from now)

US9439854

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron
Jul, 2024

(4 months from now)

Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2003

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ALOXI before it's drug patent expiration?
More Information on Dosage

ALOXI family patents

Family Patents

12. Altabax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207191 ALMIRALL Process, salts, composition and use
Aug, 2024

(5 months from now)

Drugs and Companies using RETAPAMULIN ingredient

Market Authorisation Date: 12 April, 2007

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: OINTMENT;TOPICAL

More Information on Dosage

ALTABAX family patents

Family Patents

13. Amitiza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7795312 SUCAMPO PHARMA LLC Method for treating abdominal discomfort
Sep, 2024

(5 months from now)

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 31 January, 2006

Treatment: Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome

Dosage: CAPSULE;ORAL

How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage

AMITIZA family patents

Family Patents

14. Arikayce Kit patents expiration

ARIKAYCE KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802137 INSMED INC Sustained release of antiinfectives
Apr, 2024

(13 days from now)

US9827317 INSMED INC Sustained release of antiinfectives
Apr, 2024

(13 days from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2025
Generating Antibiotic Incentives Now (GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination anti...

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage

ARIKAYCE KIT family patents

Family Patents

15. Armonair Digihaler patents expiration

ARMONAIR DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024 TEVA PHARM Process for preparing a medicament
Sep, 2024

(5 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

16. Auryxia patents expiration

AURYXIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7767851 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(a month ago)

US9757416 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(a month ago)

US9328133 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(a month ago)

US8338642 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(a month ago)

Drugs and Companies using FERRIC CITRATE ingredient

Market Authorisation Date: 05 September, 2014

Treatment: Control of serum phosphorous levels

Dosage: TABLET;ORAL

More Information on Dosage

AURYXIA family patents

Family Patents

17. Auvi-q patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10314977 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8920377 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8313466 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8608698 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US10737028 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery
Nov, 2024

(7 months from now)

US9833573 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 10 August, 2012

Treatment: Method to treat severe allergic emergencies in patients weighing 7.5 to 15 kg (16.5 to 33 lbs)

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

AUVI-Q family patents

Family Patents

18. Bosulif patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE42376 PF PRISM CV Substituted 3-cyanoquinolines
Apr, 2024

(18 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE42376

(Pediatric)

PF PRISM CV Substituted 3-cyanoquinolines
Oct, 2024

(6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 26, 2030
New Product (NP) Sep 26, 2026
Pediatric Exclusivity (PED) Mar 26, 2027

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Market Authorisation Date: 26 September, 2023

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage

BOSULIF family patents

Family Patents

19. Brilinta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46276 ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Oct, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Nov 5, 2023
M (M) May 9, 2025
Pediatric Exclusivity (PED) Nov 9, 2025

Drugs and Companies using TICAGRELOR ingredient

Market Authorisation Date: 20 July, 2011

Treatment: Treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction; Reduction of the rate of cardiovascular death, myocardial infarction, and ...

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage

BRILINTA family patents

Family Patents

20. Bydureon patents expiration

BYDUREON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7563871 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(20 days from now)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(20 days from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(6 months from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of ...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON family patents

Family Patents

21. Bydureon Bcise patents expiration

BYDUREON BCISE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(20 days from now)

US7563871 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(20 days from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(6 months from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of ...

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

22. Cabometyx patents expiration

Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284 EXELIXIS INC C-met modulators and method of use
Sep, 2024

(5 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

23. Children's Advil patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition
May, 2024

(a month from now)

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 27 June, 1996

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

CHILDREN'S ADVIL family patents

Family Patents

24. Children's Advil Allergy Sinus patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition
May, 2024

(a month from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 February, 2004

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

CHILDREN'S ADVIL ALLERGY SINUS family patents

Family Patents

25. Combivent Respimat patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(5 months from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage

COMBIVENT RESPIMAT family patents

Family Patents

26. Contrave patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278544 NALPROPION Compositions for affecting weight loss
Apr, 2024

(26 days from now)

US7462626 NALPROPION Compositions for affecting weight loss
Jul, 2024

(3 months from now)

US8815889 NALPROPION Compositions and methods for increasing insulin sensitivity
Jul, 2024

(3 months from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

27. Defencath patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8541393 CORMEDIX Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
Nov, 2024

(7 months from now)

US9339036 CORMEDIX Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
Nov, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 15, 2028
Generating Antibiotic Incentives Now (GAIN) Nov 15, 2033

Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient

NCE-1 date: 2032-11-15

Market Authorisation Date: 15 November, 2023

Treatment: A catheter lock solution to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through a central venous catheter

Dosage: SOLUTION;N/A

More Information on Dosage

DEFENCATH family patents

Family Patents

28. Dexilant patents expiration

Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(20 days from now)

US8722084

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(20 days from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage

DEXILANT family patents

Family Patents

29. Dexilant Solutab patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(20 days from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

DEXILANT SOLUTAB family patents

Family Patents

30. Dextenza patents expiration

DEXTENZA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254267 OCULAR THERAPEUTIX Composite hydrogel drug delivery systems
Sep, 2024

(5 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Oct 7, 2024

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 30 November, 2018

Treatment: NA

Dosage: INSERT;OPHTHALMIC

More Information on Dosage

DEXTENZA family patents

Family Patents

31. Differin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7737181 GALDERMA LABS LP Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Aug, 2024

(5 months from now)

Drugs and Companies using ADAPALENE ingredient

Market Authorisation Date: 19 June, 2007

Treatment: NA

Dosage: GEL;TOPICAL

How can I launch a generic of DIFFERIN before it's drug patent expiration?
More Information on Dosage

DIFFERIN family patents

Family Patents

32. Diprivan patents expiration

DIPRIVAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8476010 FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Dec, 2024

(8 months from now)

Drugs and Companies using PROPOFOL ingredient

Market Authorisation Date: 02 October, 1989

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DIPRIVAN before it's drug patent expiration?
More Information on Dosage

DIPRIVAN family patents

Family Patents

33. Duavee patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6479535 WYETH PHARMS 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
May, 2024

(a month from now)

Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient

Market Authorisation Date: 03 October, 2013

Treatment: Prevention of postmenopausal osteoporosis; Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage

DUAVEE family patents

Family Patents

34. Durysta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398707 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related implants
Apr, 2024

(a month from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 4, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

DURYSTA family patents

Family Patents

35. Dutrebis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(8 days from now)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 06 February, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

DUTREBIS family patents

Family Patents

36. Entresto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7468390

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
May, 2024

(2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Feb 16, 2024

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 07 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents

37. Envarsus Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9763920 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(5 months from now)

US8889186 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(5 months from now)

US8889185 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(5 months from now)

US8586084 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(5 months from now)

US8486993 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(5 months from now)

US9161907 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(5 months from now)

US10548880 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(5 months from now)

US9757362 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(5 months from now)

US8617599 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(5 months from now)

US8623410 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(5 months from now)

US11077096 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(5 months from now)

US8623411 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(5 months from now)

US8591946 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus
Aug, 2024

(5 months from now)

US7994214 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus
Aug, 2024

(5 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jul 10, 2022

Drugs and Companies using TACROLIMUS ingredient

Market Authorisation Date: 10 July, 2015

Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection in de novo transplant patient

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ENVARSUS XR before it's drug patent expiration?
More Information on Dosage

ENVARSUS XR family patents

Family Patents

38. Epiduo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7964202 GALDERMA LABS LP Method for treatment of common acne
Sep, 2024

(5 months from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Market Authorisation Date: 08 December, 2008

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

How can I launch a generic of EPIDUO before it's drug patent expiration?
More Information on Dosage

EPIDUO family patents

Family Patents

39. Equetro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6977253 VALIDUS PHARMS Methods for the treatment of bipolar disorder using carbamazepine
May, 2024

(a month from now)

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 10 December, 2004

Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of EQUETRO before it's drug patent expiration?
More Information on Dosage

EQUETRO family patents

Family Patents

40. Evekeo Odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130580 ARBOR PHARMS LLC Taste-masked pharmaceutical compositions
Apr, 2024

(24 days from now)

Drugs and Companies using AMPHETAMINE SULFATE ingredient

Market Authorisation Date: 30 January, 2019

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

EVEKEO ODT family patents

Family Patents

41. Evzio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9737669 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US10737028 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US10314977 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8608698 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8313466 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery
Nov, 2024

(7 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO family patents

Family Patents

42. Evzio (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10737028 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US10314977 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery
Nov, 2024

(7 months from now)

US8608698 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8313466 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

43. Exservan patents expiration

EXSERVAN's oppositions filed in EPO
EXSERVAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8603514 MITSUBISHI HOLDINGS Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(8 days from now)

Drugs and Companies using RILUZOLE ingredient

Market Authorisation Date: 22 November, 2019

Treatment: NA

Dosage: FILM;ORAL

More Information on Dosage

EXSERVAN family patents

Family Patents

44. Farxiga patents expiration

FARXIGA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(20 days from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Apr 30, 2024
M (M) May 8, 2026

Drugs and Companies using DAPAGLIFLOZIN ingredient

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

45. Fenoglide patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8124125 SALIX Solid dosage form comprising a fibrate
Oct, 2024

(6 months from now)

US8481078 SALIX Solid dosage form comprising a fibrate
Oct, 2024

(6 months from now)

US9173847 SALIX Tablet comprising a fibrate
Oct, 2024

(6 months from now)

US7658944 SALIX Solid dosage form comprising a fibrate
Dec, 2024

(8 months from now)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 10 August, 2007

Treatment: For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia; Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl...

Dosage: TABLET;ORAL

How can I launch a generic of FENOGLIDE before it's drug patent expiration?
More Information on Dosage

FENOGLIDE family patents

Family Patents

46. Fentora patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8092832 CEPHALON Generally linear effervescent oral fentanyl dosage form and methods of administering
Dec, 2024

(9 months from now)

US8119158 CEPHALON Effervescent oral fentanyl dosage form and methods of administering fentanyl
Dec, 2024

(9 months from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 25 September, 2006

Treatment: NA

Dosage: TABLET;BUCCAL, SUBLINGUAL

How can I launch a generic of FENTORA before it's drug patent expiration?
More Information on Dosage

FENTORA family patents

Family Patents

47. Flonase Sensimist Allergy Relief patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9320862 GLAXOSMITHKLINE CONS Fluid dispensing device
Nov, 2024

(7 months from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 02 August, 2016

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

FLONASE SENSIMIST ALLERGY RELIEF family patents

Family Patents

48. Fosrenol patents expiration

FOSRENOL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7381428 TAKEDA PHARMS USA Stabilized lanthanum carbonate compositions
Aug, 2024

(5 months from now)

US7465465 TAKEDA PHARMS USA Pharmaceutical formulation comprising lanthanum compounds
Aug, 2024

(5 months from now)

Drugs and Companies using LANTHANUM CARBONATE ingredient

Market Authorisation Date: 26 October, 2004

Treatment: Reduction of serum phosphate in patients with end stage renal disease

Dosage: TABLET, CHEWABLE;ORAL

How can I launch a generic of FOSRENOL before it's drug patent expiration?
More Information on Dosage

FOSRENOL family patents

Family Patents

49. Fotivda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6821987 AVEO PHARMS Quinoline derivatives and quinazoline derivatives having azolyl group
Apr, 2024

(a month from now)

US7166722 AVEO PHARMS N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form
Nov, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 10, 2026

Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient

NCE-1 date: 2025-03-10

Market Authorisation Date: 10 March, 2021

Treatment: A method of treating adults with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies by inhibiting the angiogenesis of blood vessels with a vascular end...

Dosage: CAPSULE;ORAL

More Information on Dosage

FOTIVDA family patents

Family Patents

50. Fycompa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6949571 EISAI INC 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
Jun, 2024

(2 months from now)

Drugs and Companies using PERAMPANEL ingredient

Market Authorisation Date: 22 October, 2012

Treatment: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older; Treatment of partial-onset seizures with or without secondarily...

Dosage: TABLET;ORAL

How can I launch a generic of FYCOMPA before it's drug patent expiration?
More Information on Dosage

FYCOMPA family patents

Family Patents

51. Givlaari patents expiration

Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9708610 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(2 months ago)

US9708615 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(17 days ago)

US10273477 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(17 days ago)

US11530408 ALNYLAM PHARMS INC Therapeutic compositions
May, 2024

(a month from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 20, 2024
Orphan Drug Exclusivity (ODE) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 2023-11-21

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GIVLAARI family patents

Family Patents

52. Hycamtin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8158645 NOVARTIS Compound, corresponding compositions, preparation and/or treatment methods
Dec, 2024

(8 months from now)

Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 11 October, 2007

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

HYCAMTIN family patents

Family Patents

53. Ilevro patents expiration

ILEVRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947295 NOVARTIS Ophthalmic compositions containing a synergistic combination of two polymers
Jun, 2024

(2 months from now)

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 16 October, 2012

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

How can I launch a generic of ILEVRO before it's drug patent expiration?
More Information on Dosage

ILEVRO family patents

Family Patents

54. Invokamet patents expiration

INVOKAMET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(4 months from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2014

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage

INVOKAMET family patents

Family Patents

55. Invokamet Xr patents expiration

INVOKAMET XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(4 months from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage

INVOKAMET XR family patents

Family Patents

56. Ionsys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6975902 THE MEDICINES CO Reservoir and a series of related reservoirs for use in an electrotransport drug delivery device and devices comprised thereof
Apr, 2024

(6 days from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: NA

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

More Information on Dosage

IONSYS family patents

Family Patents

57. Isentress patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(8 days from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 12 October, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage

ISENTRESS family patents

Family Patents

58. Ixempra Kit patents expiration

IXEMPRA KIT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7312237 R-PHARM US LLC Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
Aug, 2024

(4 months from now)

Drugs and Companies using IXABEPILONE ingredient

Market Authorisation Date: 16 October, 2007

Treatment: Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of IXEMPRA KIT before it's drug patent expiration?
More Information on Dosage

IXEMPRA KIT family patents

Family Patents

59. Kuvan patents expiration

KUVAN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8067416 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(7 months from now)

US7612073 BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
Nov, 2024

(7 months from now)

US9433624 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(7 months from now)

US7727987 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
Nov, 2024

(7 months from now)

US8318745 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
Nov, 2024

(7 months from now)

US7566714 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(7 months from now)

USRE43797 BIOMARIN PHARM Methods of administering tetrahydrobiopterin
Nov, 2024

(7 months from now)

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Market Authorisation Date: 13 December, 2007

Treatment: Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobio...

Dosage: TABLET;ORAL

How can I launch a generic of KUVAN before it's drug patent expiration?
More Information on Dosage

KUVAN family patents

Family Patents

60. Kynmobi patents expiration

KYNMOBI's oppositions filed in EPO
KYNMOBI Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8603514 SUNOVION PHARMS INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(8 days from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 21, 2023

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 May, 2020

Treatment: NA

Dosage: FILM;SUBLINGUAL

More Information on Dosage

KYNMOBI family patents

Family Patents

61. Latisse patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101161 ALLERGAN Method of enhancing hair growth
May, 2024

(a month from now)

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 24 December, 2008

Treatment: Method of stimulating hair growth; Method of increasing hair growth

Dosage: SOLUTION/DROPS;TOPICAL

How can I launch a generic of LATISSE before it's drug patent expiration?
More Information on Dosage

LATISSE family patents

Family Patents

62. Latuda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174975

(Pediatric)

SUNOVION PHARMS INC Remedy for integration dysfunction syndrome
Aug, 2024

(4 months from now)

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 October, 2010

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage

LATUDA family patents

Family Patents

63. Lazanda patents expiration

LAZANDA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8216604 BTCP PHARMA Method of managing or treating pain
Oct, 2024

(6 months from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 30 June, 2011

Treatment: Management of breakthrough pain in patients with cancer

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

LAZANDA family patents

Family Patents

64. Leqvio patents expiration

Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9708610 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(2 months ago)

US9708615 NOVARTIS Therapeutic compositions
Mar, 2024

(17 days ago)

US10669544 NOVARTIS Therapeutic compositions
Mar, 2024

(17 days ago)

US10273477 NOVARTIS Therapeutic compositions
Mar, 2024

(17 days ago)

US11530408 NOVARTIS Therapeutic compositions
May, 2024

(a month from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: 2025-12-22

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

LEQVIO family patents

Family Patents

65. Linzess patents expiration

LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7704947 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(a month ago)

US7745409 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(a month ago)

US8080526 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(a month ago)

US7371727 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(a month ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Jun 12, 2026

Drugs and Companies using LINACLOTIDE ingredient

Market Authorisation Date: 30 August, 2012

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage

LINZESS family patents

Family Patents

66. Livalo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557993

(Pediatric)

KOWA CO Crystalline forms of pitavastatin calcium
Aug, 2024

(4 months from now)

US7022713

(Pediatric)

KOWA CO Hyperlipemia therapeutic agent
Aug, 2024

(4 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) May 16, 2022
Pediatric Exclusivity (PED) Nov 16, 2022

Drugs and Companies using PITAVASTATIN CALCIUM ingredient

Market Authorisation Date: 03 August, 2009

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of LIVALO before it's drug patent expiration?
More Information on Dosage

LIVALO family patents

Family Patents

67. Lonhala Magnair Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7458372 SUNOVION RESP Inhalation therapy device
Nov, 2024

(7 months from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage

LONHALA MAGNAIR KIT family patents

Family Patents

68. Lupkynis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7332472 AURINIA Cyclosporine analogue mixtures and their use as immunomodulating agents
Oct, 2024

(6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 22, 2026

Drugs and Companies using VOCLOSPORIN ingredient

NCE-1 date: 2025-01-22

Market Authorisation Date: 22 January, 2021

Treatment: Treatment of patients with active lupus nephritis

Dosage: CAPSULE;ORAL

More Information on Dosage

LUPKYNIS family patents

Family Patents

69. Lynparza patents expiration

LYNPARZA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7981889 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(6 months from now)

US7449464 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 8, 2027
New Indication (I) Mar 11, 2025

Drugs and Companies using OLAPARIB ingredient

Market Authorisation Date: 17 August, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage

LYNPARZA family patents

Family Patents

70. Mavenclad patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7888328 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(16 days from now)

US8785415 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(16 days from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 29, 2022

Drugs and Companies using CLADRIBINE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusi...

Dosage: TABLET;ORAL

How can I launch a generic of MAVENCLAD before it's drug patent expiration?
More Information on Dosage

MAVENCLAD family patents

Family Patents

71. Megace Es patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101549 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(27 days from now)

US7101576 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(27 days from now)

US9101540 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(27 days from now)

US9107827 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(27 days from now)

US9040088 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(27 days from now)

Drugs and Companies using MEGESTROL ACETATE ingredient

Market Authorisation Date: 05 July, 2005

Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)

Dosage: SUSPENSION;ORAL

How can I launch a generic of MEGACE ES before it's drug patent expiration?
More Information on Dosage

MEGACE ES family patents

Family Patents

72. Methylin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7691880 SPECGX LLC Methylphenidate solution and associated methods of administration and production
Oct, 2024

(6 months from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2002

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of METHYLIN before it's drug patent expiration?
More Information on Dosage

METHYLIN family patents

Family Patents

73. Mirvaso patents expiration

MIRVASO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859551 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
May, 2024

(a month from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 23 August, 2013

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

How can I launch a generic of MIRVASO before it's drug patent expiration?
More Information on Dosage

MIRVASO family patents

Family Patents

74. Movantik patents expiration

MOVANTIK's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7056500 REDHILL Polymer conjugates of opioid antagonists
Jun, 2024

(3 months from now)

US8067431 REDHILL Chemically modified small molecules
Dec, 2024

(8 months from now)

Drugs and Companies using NALOXEGOL OXALATE ingredient

Market Authorisation Date: 16 September, 2014

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

How can I launch a generic of MOVANTIK before it's drug patent expiration?
More Information on Dosage

MOVANTIK family patents

Family Patents

75. Moviprep patents expiration

MOVIPREP's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7169381 SALIX PHARMS Colon cleansing compositions and methods
Sep, 2024

(5 months from now)

US7658914 SALIX PHARMS Colon cleansing compositions
Sep, 2024

(5 months from now)

How can I launch a generic of MOVIPREP before it's drug patent expiration?
More Information on Dosage

MOVIPREP family patents

Family Patents

76. Mulpleta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7601746 SHIONOGI INC Compounds exhibiting thrombopoietin receptor agonism
Sep, 2024

(5 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 31, 2023

Drugs and Companies using LUSUTROMBOPAG ingredient

NCE-1 date: 2022-07-31

Market Authorisation Date: 31 July, 2018

Treatment: Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure

Dosage: TABLET;ORAL

More Information on Dosage

MULPLETA family patents

Family Patents

77. Myrbetriq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE44872

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(a month from now)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(a month from now)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(a month from now)

US8835474

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(a month from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Mar 25, 2024
Pediatric Exclusivity (PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 28 June, 2012

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage

MYRBETRIQ family patents

Family Patents

78. Myrbetriq Granules patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(a month from now)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(a month from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 25, 2024
Pediatric Exclusivity (PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 25 March, 2021

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

MYRBETRIQ GRANULES family patents

Family Patents

79. Naloxone Hydrochloride (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7918823 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US10737028 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery
Nov, 2024

(7 months from now)

US8313466 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US10314977 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US8608698 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery
Nov, 2024

(7 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 February, 2022

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents

Family Patents

80. Naropin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8162915 FRESENIUS KABI USA Connector for packings containing medical liquids, and corresponding packing for medical liquids
May, 2024

(a month from now)

Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 September, 1996

Treatment: NA

Dosage: SOLUTION;INJECTION

How can I launch a generic of NAROPIN before it's drug patent expiration?
More Information on Dosage

NAROPIN family patents

Family Patents

81. Nascobal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415007 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Jul, 2024

(4 months from now)

US7879349 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Aug, 2024

(4 months from now)

US7229636 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Aug, 2024

(4 months from now)

US8003353 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Aug, 2024

(4 months from now)

Drugs and Companies using CYANOCOBALAMIN ingredient

Market Authorisation Date: 31 January, 2005

Treatment: Supplement for vitamin b12 deficiencies; Cyanocobalamin administration through nasal infusion; Nasal administration of cyanocobalamin

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of NASCOBAL before it's drug patent expiration?
More Information on Dosage

NASCOBAL family patents

Family Patents

82. Ninlaro patents expiration

NINLARO's oppositions filed in EPO
Can you believe NINLARO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8546608 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same
Aug, 2024

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233115 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same
Aug, 2024

(4 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 20, 2022

Drugs and Companies using IXAZOMIB CITRATE ingredient

Market Authorisation Date: 20 November, 2015

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

How can I launch a generic of NINLARO before it's drug patent expiration?
More Information on Dosage

NINLARO family patents

Family Patents

83. Noctiva patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7799761 SERENITY PHARMS LLC Pharmaceutical compositions including low dosages of desmopressin
Sep, 2024

(6 months from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 03 March, 2017

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

NOCTIVA family patents

Family Patents

84. Nourianz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7541363 KYOWA KIRIN Microcrystal
Nov, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 27, 2024

Drugs and Companies using ISTRADEFYLLINE ingredient

NCE-1 date: 2023-08-28

Market Authorisation Date: 27 August, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

NOURIANZ family patents

Family Patents

85. Nucynta Er patents expiration

NUCYNTA ER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114383 COLLEGIUM PHARM INC Abuse-proofed dosage form
Oct, 2024

(6 months from now)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Market Authorisation Date: 25 August, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of NUCYNTA ER before it's drug patent expiration?
More Information on Dosage

NUCYNTA ER family patents

Family Patents

86. Nuvigil patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346

(Pediatric)

CEPHALON Pharmaceutical formulations of modafinil
May, 2024

(2 months from now)

US7132570

(Pediatric)

CEPHALON Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Jun, 2024

(2 months from now)

Drugs and Companies using ARMODAFINIL ingredient

Market Authorisation Date: 15 June, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of NUVIGIL before it's drug patent expiration?
More Information on Dosage

NUVIGIL family patents

Family Patents

87. Nuzyra patents expiration

Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7553828 PARATEK PHARMS INC 9-aminomethyl substituted minocycline compounds
Jun, 2024

(2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 2, 2023
Generating Antibiotic Incentives Now (GAIN) Oct 2, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: 2027-10-03

Market Authorisation Date: 02 October, 2018

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

NUZYRA family patents

Family Patents

88. Nymalize patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8517997 AZURITY Dispenser for medicaments and method and apparatus for making same
May, 2024

(a month from now)

Drugs and Companies using NIMODIPINE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of NYMALIZE before it's drug patent expiration?
More Information on Dosage

NYMALIZE family patents

Family Patents

89. Ofev patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7119093 BOEHRINGER INGELHEIM 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Feb, 2024

(a month ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 6, 2026
Pediatric Exclusivity (PED) Mar 6, 2027

Drugs and Companies using NINTEDANIB ESYLATE ingredient

Market Authorisation Date: 15 October, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of OFEV before it's drug patent expiration?
More Information on Dosage

OFEV family patents

Family Patents

90. Omegaven patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350186 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Nov, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jul 27, 2025

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

Market Authorisation Date: 27 July, 2018

Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage

OMEGAVEN family patents

Family Patents

91. Omontys patents expiration

Can you believe OMONTYS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7414105 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(a month from now)

US7084245 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(a month from now)

US7528104 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(a month from now)

US7919118 TAKEDA PHARMS USA Spacer moiety for poly (ethylene glycol) modified peptide based compounds
May, 2024

(a month from now)

Drugs and Companies using PEGINESATIDE ACETATE ingredient

Market Authorisation Date: 27 March, 2012

Treatment: Treatment of anemia due to chronic kidney disease

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage

OMONTYS family patents

Family Patents

92. Onzetra Xsail patents expiration

ONZETRA XSAIL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119932 CURRAX Nasal delivery device
Apr, 2024

(28 days from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: NA

Dosage: POWDER;NASAL

More Information on Dosage

ONZETRA XSAIL family patents

Family Patents

93. Opana Er patents expiration

OPANA ER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114383 ENDO PHARMS Abuse-proofed dosage form
Aug, 2024

(4 months from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 09 December, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

OPANA ER family patents

Family Patents

94. Oracea patents expiration

ORACEA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8394406 GALDERMA LABS LP Once daily formulations of tetracyclines
Apr, 2024

(12 days from now)

US8709478 GALDERMA LABS LP Once daily formulations of tetracyclines
Apr, 2024

(12 days from now)

US8394405 GALDERMA LABS LP Once daily formulations of tetracyclines
Apr, 2024

(12 days from now)

US8470364 GALDERMA LABS LP Once daily formulations of tetracyclines
Apr, 2024

(12 days from now)

Drugs and Companies using DOXYCYCLINE ingredient

Market Authorisation Date: 26 May, 2006

Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea

Dosage: CAPSULE;ORAL

How can I launch a generic of ORACEA before it's drug patent expiration?
More Information on Dosage

ORACEA family patents

Family Patents

95. Orenitram patents expiration

ORENITRAM's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9050311 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(a month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278901 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(a month from now)

US8252839 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(a month from now)

US9422223 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(a month from now)

US7544713 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Jul, 2024

(3 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 18, 2026

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Market Authorisation Date: 20 December, 2013

Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ORENITRAM before it's drug patent expiration?
More Information on Dosage

ORENITRAM family patents

Family Patents

96. Oriahnn (copackaged) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(5 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023
New Product (NP) May 29, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: 2022-07-23

Market Authorisation Date: 29 May, 2020

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ORIAHNN (COPACKAGED) before it's drug patent expiration?
More Information on Dosage

ORIAHNN (COPACKAGED) family patents

Family Patents

97. Orilissa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176211 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Jul, 2024

(3 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: 2022-07-23

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis

Dosage: TABLET;ORAL

How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage

ORILISSA family patents

Family Patents

98. Orserdu patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399520 STEMLINE THERAP Selective estrogen receptor modulator
Dec, 2024

(8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 27, 2028

Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient

NCE-1 date: 2027-01-27

Market Authorisation Date: 27 January, 2023

Treatment: Treatment of an er-positive breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

ORSERDU family patents

Family Patents

99. Oxaydo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492443 ZYLA Abuse deterrent compositions and methods of making same
May, 2024

(2 months from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of OXAYDO before it's drug patent expiration?
More Information on Dosage

OXAYDO family patents

Family Patents

100. Ozempic patents expiration

What is Ozempic?

Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.

What is the Ozempic controversy?

The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.

OZEMPIC's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(a month from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule (D) Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage

OZEMPIC family patents

Family Patents

101. Pepaxto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6992207 ONCOPEPTIDES AB Melphalan derivatives and their use as cancer chemotherapeutic drugs
Jun, 2024

(2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 26, 2028
New Chemical Entity Exclusivity (NCE) Feb 26, 2026

Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient

NCE-1 date: 2025-02-26

Market Authorisation Date: 26 February, 2021

Treatment: In combination with dexamethasone to treat relapsed or refactory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received a...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

PEPAXTO family patents

Family Patents

102. Ponvory patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43728 JANSSEN PHARMS Thiazolidin-4-one derivatives
Nov, 2024

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018 JANSSEN PHARMS Thiazolidin-4-one-derivatives
Nov, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 2025-03-18

Market Authorisation Date: 18 March, 2021

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...

Dosage: TABLET;ORAL

More Information on Dosage

PONVORY family patents

Family Patents

103. Prevymis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8513255 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(a month from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 5, 2030
New Dosing Schedule (D) Aug 2, 2026
New Indication (I) Jun 5, 2026

Drugs and Companies using LETERMOVIR ingredient

Market Authorisation Date: 08 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

PREVYMIS family patents

Family Patents

104. Prezcobix patents expiration

PREZCOBIX's oppositions filed in EPO
PREZCOBIX Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(a month ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Aug, 2024

(4 months from now)

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

Market Authorisation Date: 29 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of PREZCOBIX before it's drug patent expiration?
More Information on Dosage

PREZCOBIX family patents

Family Patents

105. Prezista patents expiration

PREZISTA's oppositions filed in EPO
PREZISTA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(a month ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Aug, 2024

(4 months from now)

Drugs and Companies using DARUNAVIR ingredient

Market Authorisation Date: 16 December, 2011

Treatment: NA

Dosage: SUSPENSION;ORAL

How can I launch a generic of PREZISTA before it's drug patent expiration?
More Information on Dosage

PREZISTA family patents

Family Patents

106. Prialt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8653033 TERSERA Method for administering omega-conopeptide
Oct, 2024

(6 months from now)

US8765680 TERSERA Method for administering omega-conopeptide
Oct, 2024

(6 months from now)

US9707270 TERSERA Method for administering ω-conopeptide
Oct, 2024

(6 months from now)

Drugs and Companies using ZICONOTIDE ACETATE ingredient

Market Authorisation Date: 28 December, 2004

Treatment: Analgesia; Treatment of pain; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine

Dosage: INJECTABLE;INTRATHECAL

More Information on Dosage

PRIALT family patents

Family Patents

107. Probuphine patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7736665 TITAN PHARMS Implantable polymeric device for sustained release of buprenorphine
Apr, 2024

(30 days from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 26 May, 2016

Treatment: For opioid dependence

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

PROBUPHINE family patents

Family Patents

108. Protonix patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7553498 WYETH PHARMS Pantoprazole multiparticulate formulations
Sep, 2024

(6 months from now)

US7838027 WYETH PHARMS Pantoprazole multiparticulate formulations
Sep, 2024

(6 months from now)

US7550153 WYETH PHARMS Pantoprazole multiparticulate formulations
Sep, 2024

(6 months from now)

Drugs and Companies using PANTOPRAZOLE SODIUM ingredient

Market Authorisation Date: 14 November, 2007

Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd

Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL

How can I launch a generic of PROTONIX before it's drug patent expiration?
More Information on Dosage

PROTONIX family patents

Family Patents

109. Provigil patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346

(Pediatric)

CEPHALON Pharmaceutical formulations of modafinil
May, 2024

(2 months from now)

Drugs and Companies using MODAFINIL ingredient

Market Authorisation Date: 24 December, 1998

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of PROVIGIL before it's drug patent expiration?
More Information on Dosage

PROVIGIL family patents

Family Patents

110. Rayos patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8394407 HORIZON Delayed release tablet with defined core geometry
Apr, 2024

(28 days from now)

US9186332 HORIZON Delayed release tablet with defined core geometry
Apr, 2024

(28 days from now)

US9040085 HORIZON Delayed release tablet with defined core geometry
Apr, 2024

(28 days from now)

US8309124 HORIZON Delayed release tablet with defined core geometry
Apr, 2024

(28 days from now)

Drugs and Companies using PREDNISONE ingredient

Market Authorisation Date: 26 July, 2012

Treatment: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet; Treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of RAYOS before it's drug patent expiration?
More Information on Dosage

RAYOS family patents

Family Patents

111. Relistor patents expiration

RELISTOR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376584 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone
Apr, 2024

(13 days from now)

US9669096 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone
Apr, 2024

(13 days from now)

US8552025 SALIX PHARMS Stable methylnaltrexone preparation
Apr, 2024

(13 days from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Market Authorisation Date: 24 April, 2008

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of RELISTOR before it's drug patent expiration?
More Information on Dosage

RELISTOR family patents

Family Patents

112. Remodulin patents expiration

REMODULIN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9199908 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(a month from now)

US10076505 UNITED THERAP Inhalation formulations of Treprostinil
Dec, 2024

(8 months from now)

US10695308 UNITED THERAP Inhalation formulations of treprostinil
Dec, 2024

(8 months from now)

US9713599 UNITED THERAP Parenteral formulations of treprostinil
Dec, 2024

(8 months from now)

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 21 May, 2002

Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating a human patient suffering...

Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS

How can I launch a generic of REMODULIN before it's drug patent expiration?
More Information on Dosage

REMODULIN family patents

Family Patents

113. Restasis patents expiration

RESTASIS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629111 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(5 months from now)

US8633162 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(5 months from now)

US8685930 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(5 months from now)

US8642556 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(5 months from now)

US9248191 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(5 months from now)

US8648048 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(5 months from now)

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 December, 2002

Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

How can I launch a generic of RESTASIS before it's drug patent expiration?
More Information on Dosage

RESTASIS family patents

Family Patents

114. Revlimid patents expiration

REVLIMID's oppositions filed in EPO
Can you believe REVLIMID received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7855217 BRISTOL MYERS SQUIBB Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
Nov, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 28, 2026

Drugs and Companies using LENALIDOMIDE ingredient

Market Authorisation Date: 27 December, 2005

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of REVLIMID before it's drug patent expiration?
More Information on Dosage

REVLIMID family patents

Family Patents

115. Rhofade patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420688 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
Aug, 2024

(4 months from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 January, 2017

Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream

Dosage: CREAM;TOPICAL

How can I launch a generic of RHOFADE before it's drug patent expiration?
More Information on Dosage

RHOFADE family patents

Family Patents

116. Rubraca patents expiration

RUBRACA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7531530 CLOVIS ONCOLOGY INC Therapeutic compounds
Jul, 2024

(3 months from now)

US7351701 CLOVIS ONCOLOGY INC Therapeutic compounds
Jul, 2024

(3 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 6, 2025

Drugs and Companies using RUCAPARIB CAMSYLATE ingredient

Market Authorisation Date: 19 December, 2016

Treatment: A method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; A method for treating ovarian cancer by admin...

Dosage: TABLET;ORAL

More Information on Dosage

RUBRACA family patents

Family Patents

117. Saxenda patents expiration

SAXENDA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(a month from now)

US7762994

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Nov, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Dec 4, 2023

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 23 December, 2014

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage

SAXENDA family patents

Family Patents

118. Soolantra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470788 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(27 days from now)

US7550440 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(27 days from now)

US8815816 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(27 days from now)

US8093219 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(27 days from now)

US8080530 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(27 days from now)

US8415311 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(27 days from now)

US11033565 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(27 days from now)

Drugs and Companies using IVERMECTIN ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of inflammatory lesions of rosacea.

Dosage: CREAM;TOPICAL

How can I launch a generic of SOOLANTRA before it's drug patent expiration?
More Information on Dosage

SOOLANTRA family patents

Family Patents

119. Spiriva Respimat patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(5 months from now)

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 24 September, 2014

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

How can I launch a generic of SPIRIVA RESPIMAT before it's drug patent expiration?
More Information on Dosage

SPIRIVA RESPIMAT family patents

Family Patents

120. Stiolto Respimat patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(5 months from now)

Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 21 May, 2015

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

STIOLTO RESPIMAT family patents

Family Patents

121. Striverdi Respimat patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(5 months from now)

Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient

Market Authorisation Date: 31 July, 2014

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

STRIVERDI RESPIMAT family patents

Family Patents

122. Suboxone patents expiration

SUBOXONE's oppositions filed in EPO
SUBOXONE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8603514 INDIVIOR INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(8 days from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 August, 2010

Treatment: Treatment of opioid dependence/sublingual or buccal application

Dosage: FILM;BUCCAL, SUBLINGUAL

How can I launch a generic of SUBOXONE before it's drug patent expiration?
More Information on Dosage

SUBOXONE family patents

Family Patents

123. Sumavel Dosepro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8287489 ENDO VENTURES LTD Device for readying a needle free injector for delivery
Dec, 2024

(8 months from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 15 July, 2009

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

SUMAVEL DOSEPRO family patents

Family Patents

124. Sustol patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252304 HERON THERAPS INC Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
Sep, 2024

(6 months from now)

US9913910 HERON THERAPS INC Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
Sep, 2024

(6 months from now)

US10357570 HERON THERAPS INC Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
Sep, 2024

(6 months from now)

US8252305 HERON THERAPS INC Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron
Sep, 2024

(6 months from now)

US8715710 HERON THERAPS INC Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
Sep, 2024

(6 months from now)

Drugs and Companies using GRANISETRON ingredient

Market Authorisation Date: 09 August, 2016

Treatment: Prophylactic treatment of nausea and vomiting, including prevention of acute and delayed nausea and vomiting associated chemotherapy; Treatment or prevention of nausea and vomiting

Dosage: INJECTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

SUSTOL family patents

Family Patents

125. Symbicort patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8875699 ASTRAZENECA Inhaler cap strap
Nov, 2024

(7 months from now)

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient

Market Authorisation Date: 21 July, 2006

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of SYMBICORT before it's drug patent expiration?
More Information on Dosage

SYMBICORT family patents

Family Patents

126. Sympazan patents expiration

SYMPAZAN's oppositions filed in EPO
SYMPAZAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8603514 AQUESTIVE Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(8 days from now)

Drugs and Companies using CLOBAZAM ingredient

Market Authorisation Date: 01 November, 2018

Treatment: NA

Dosage: FILM;ORAL

More Information on Dosage

SYMPAZAN family patents

Family Patents

127. Symtuza patents expiration

SYMTUZA's oppositions filed in EPO
SYMTUZA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(a month ago)

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 17 July, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of SYMTUZA before it's drug patent expiration?
More Information on Dosage

SYMTUZA family patents

Family Patents

128. Technivie patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(4 months from now)

US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(4 months from now)

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Market Authorisation Date: 24 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

TECHNIVIE family patents

Family Patents

129. Tobi Podhaler patents expiration

TOBI PODHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47526 MYLAN SPECIALITY LP Aerosolization apparatus with air inlet shield
Apr, 2024

(14 days from now)

US8069851 MYLAN SPECIALITY LP Aeorosolization apparatus with air inlet shield
Sep, 2024

(5 months from now)

US11484671 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncture alignment guide
Nov, 2024

(7 months from now)

Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 22 March, 2013

Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa

Dosage: POWDER;INHALATION

More Information on Dosage

TOBI PODHALER family patents

Family Patents

130. Tpoxx patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8124643 SIGA TECHNOLOGIES Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jun, 2024

(2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8530509 SIGA TECHNOLOGIES Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jun, 2024

(2 months from now)

US8802714 SIGA TECHNOLOGIES Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jun, 2024

(2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 13, 2023

Drugs and Companies using TECOVIRIMAT ingredient

NCE-1 date: 2022-07-13

Market Authorisation Date: 18 May, 2022

Treatment: Tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

TPOXX family patents

Family Patents

131. Tukysa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7452895 SEAGEN Quinazoline analogs as receptor tyrosine kinase inhibitors
Nov, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 19, 2030
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
New Indication (I) Jan 19, 2026

Drugs and Companies using TUCATINIB ingredient

NCE-1 date: 2024-04-17

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

TUKYSA family patents

Family Patents

132. Ulesfia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7294342 SHIONOGI INC Ectoparasite asphyxiator compositions and methods for their application
May, 2024

(a month from now)

Drugs and Companies using BENZYL ALCOHOL ingredient

Market Authorisation Date: 09 April, 2009

Treatment: Topical treatment of lice infestations

Dosage: LOTION;TOPICAL

How can I launch a generic of ULESFIA before it's drug patent expiration?
More Information on Dosage

ULESFIA family patents

Family Patents

133. Vandazole patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456207 TEVA PHARMS Vaginal pharmaceutical compositions and methods for preparing them
Sep, 2024

(5 months from now)

Drugs and Companies using METRONIDAZOLE ingredient

Market Authorisation Date: 20 May, 2005

Treatment: NA

Dosage: GEL;VAGINAL

More Information on Dosage

VANDAZOLE family patents

Family Patents

134. Varithena patents expiration

VARITHENA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7731986 PROVENSIS Therapeutic foam
Nov, 2024

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8122917 PROVENSIS Apparatus and method for dispensing foam
Sep, 2024

(5 months from now)

Drugs and Companies using POLIDOCANOL ingredient

Market Authorisation Date: 25 November, 2013

Treatment: A method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

VARITHENA family patents

Family Patents

135. Veltassa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889115 VIFOR PHARMA Ion binding polymers and uses thereof
Mar, 2024

(4 days from now)

US8778324 VIFOR PHARMA Ion binding polymers and uses thereof
Mar, 2024

(4 days from now)

US8475780 VIFOR PHARMA Ion binding polymers and uses thereof
Mar, 2024

(4 days from now)

US8287847 VIFOR PHARMA Ion binding polymers and uses thereof
Mar, 2024

(4 days from now)

US10485821 VIFOR PHARMA Ion binding polymers and uses thereof
Mar, 2024

(4 days from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Oct 2, 2026
New Strength (NS) Oct 2, 2026

Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient

Market Authorisation Date: 21 October, 2015

Treatment: Treatment of hyperkalemia

Dosage: POWDER;ORAL

How can I launch a generic of VELTASSA before it's drug patent expiration?
More Information on Dosage

VELTASSA family patents

Family Patents

136. Victoza patents expiration

VICTOZA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(a month from now)

US7762994

(Pediatric)

NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Nov, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jun 17, 2022
Pediatric Exclusivity (PED) Dec 17, 2022

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 25 January, 2010

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage

VICTOZA family patents

Family Patents

137. Victrelis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43298 MERCK SHARP DOHME Peptides as NS3-serine protease inhibitors of hepatitis C virus
Dec, 2024

(8 months from now)

Drugs and Companies using BOCEPREVIR ingredient

Market Authorisation Date: 13 May, 2011

Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease

Dosage: CAPSULE;ORAL

More Information on Dosage

VICTRELIS family patents

Family Patents

138. Viekira Pak (copackaged) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(4 months from now)

US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(4 months from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

Market Authorisation Date: 19 December, 2014

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

VIEKIRA PAK (COPACKAGED) family patents

Family Patents

139. Viekira Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(4 months from now)

US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(4 months from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Market Authorisation Date: 22 July, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

VIEKIRA XR family patents

Family Patents

140. Vizamyl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8236282 GE HEALTHCARE Benzothiazole derivative compounds, compositions and uses
May, 2024

(a month from now)

Drugs and Companies using FLUTEMETAMOL F-18 ingredient

Market Authorisation Date: 25 October, 2013

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage

VIZAMYL family patents

Family Patents

141. Vyndamax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7214695 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2024

(8 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214696 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2024

(8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2024
Orphan Drug Exclusivity (ODE) May 3, 2026

Drugs and Companies using TAFAMIDIS ingredient

NCE-1 date: 2023-05-04

Market Authorisation Date: 03 May, 2019

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE;ORAL

How can I launch a generic of VYNDAMAX before it's drug patent expiration?
More Information on Dosage

VYNDAMAX family patents

Family Patents

142. Vyndaqel patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7214695 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2024

(8 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214696 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2024

(8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2024
Orphan Drug Exclusivity (ODE) May 3, 2026

Drugs and Companies using TAFAMIDIS MEGLUMINE ingredient

NCE-1 date: 2023-05-04

Market Authorisation Date: 03 May, 2019

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE;ORAL

More Information on Dosage

VYNDAQEL family patents

Family Patents

143. Winlevi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211295 SUN PHARM 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2024

(3 months from now)

US8865690 SUN PHARM 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2024

(3 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 26, 2025

Drugs and Companies using CLASCOTERONE ingredient

NCE-1 date: 2024-08-26

Market Authorisation Date: 26 August, 2020

Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate

Dosage: CREAM;TOPICAL

More Information on Dosage

WINLEVI family patents

Family Patents

144. Xarelto patents expiration

XARELTO's oppositions filed in EPO
XARELTO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157456 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Aug, 2024

(5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415053 JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
Nov, 2024

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Dec 20, 2024
Pediatric Exclusivity (PED) Jun 20, 2025

Drugs and Companies using RIVAROXABAN ingredient

Market Authorisation Date: 20 December, 2021

Treatment: Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Treatment of deep vein thrombosis (dvt); Reduction of risk of major cardiovascular events (cv death, mi, and st...

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage

XARELTO family patents

Family Patents

145. Xeglyze patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9839631 DR REDDYS LABS SA Methods and compositions for controlling ectoparasites
Jul, 2024

(3 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9357783 DR REDDYS LABS SA Methods and compositions for controlling ectoparasites
Jul, 2024

(3 months from now)

US8212038 DR REDDYS LABS SA Methods and compositions for controlling ectoparasites
Jul, 2024

(3 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 24, 2025

Drugs and Companies using ABAMETAPIR ingredient

NCE-1 date: 2024-07-24

Market Authorisation Date: 24 July, 2020

Treatment: Topical treatment of head lice infestation in patients 6 months of age and older

Dosage: LOTION;TOPICAL

More Information on Dosage

XEGLYZE family patents

Family Patents

146. Xhance patents expiration

XHANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8522778 OPTINOSE US INC Nasal devices
Apr, 2024

(25 days from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 18 September, 2017

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

XHANCE family patents

Family Patents

147. Xifaxan patents expiration

XIFAXAN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7612199 SALIX PHARMS Polymorphic forms α, β, and γ of rifaximin
Jun, 2024

(2 months from now)

US7902206 SALIX PHARMS Polymorphic forms α, β and γ of rifaximin
Jun, 2024

(2 months from now)

US7045620 SALIX PHARMS Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations
Jun, 2024

(2 months from now)

US8158781 SALIX PHARMS Polymorphic forms α, β and γ of rifaximin
Jun, 2024

(2 months from now)

US8835452 SALIX PHARMS Polymorphic forms α, β and γ of rifaximin
Jun, 2024

(2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8853231 SALIX PHARMS Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
Jun, 2024

(2 months from now)

US8158644 SALIX PHARMS Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
Jun, 2024

(2 months from now)

Drugs and Companies using RIFAXIMIN ingredient

Market Authorisation Date: 25 May, 2004

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of XIFAXAN before it's drug patent expiration?
More Information on Dosage

XIFAXAN family patents

Family Patents

148. Xiidra patents expiration

Can you believe XIIDRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7745460 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(7 months from now)

US7928122 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216174 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(7 months from now)

US10124000 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(7 months from now)

US7790743 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(7 months from now)

Drugs and Companies using LIFITEGRAST ingredient

Market Authorisation Date: 11 July, 2016

Treatment: Treatment of the signs and symptoms of dry eye disease (ded); Treatment of signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of XIIDRA before it's drug patent expiration?
More Information on Dosage

XIIDRA family patents

Family Patents

149. Xopenex Hfa patents expiration

XOPENEX HFA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7256310 SUNOVION Levalbuterol salt
Oct, 2024

(6 months from now)

Drugs and Companies using LEVALBUTEROL TARTRATE ingredient

Market Authorisation Date: 11 March, 2005

Treatment: Treatment or prevention of bronchospasm or asthmatic symptoms

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of XOPENEX HFA before it's drug patent expiration?
More Information on Dosage

XOPENEX HFA family patents

Family Patents

150. Xyrem patents expiration

XYREM Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7668730 JAZZ PHARMS Sensitive drug distribution system and method
Jun, 2024

(2 months from now)

US7668730

(Pediatric)

JAZZ PHARMS Sensitive drug distribution system and method
Dec, 2024

(8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 26, 2025
Pediatric Exclusivity (PED) Apr 26, 2026

Drugs and Companies using SODIUM OXYBATE ingredient

Market Authorisation Date: 17 July, 2002

Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution

Dosage: SOLUTION;ORAL

How can I launch a generic of XYREM before it's drug patent expiration?
More Information on Dosage

XYREM family patents

Family Patents

151. Zavzpret patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7220862 PFIZER Calcitonin gene related peptide receptor antagonists
Jan, 2024

(2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 9, 2028

Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient

NCE-1 date: 2027-03-10

Market Authorisation Date: 09 March, 2023

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

ZAVZPRET family patents

Family Patents

152. Zokinvy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7838531 EIGER BIOPHARMS Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Jul, 2024

(4 months from now)

US8828356 EIGER BIOPHARMS Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Oct, 2024

(6 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 20, 2027
New Chemical Entity Exclusivity (NCE) Nov 20, 2025

Drugs and Companies using LONAFARNIB ingredient

NCE-1 date: 2024-11-20

Market Authorisation Date: 20 November, 2020

Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)

Dosage: CAPSULE;ORAL

More Information on Dosage

ZOKINVY family patents

Family Patents

153. Zontivity patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7713999 XSPIRE PHARMA Thrombin receptor antagonists
May, 2024

(2 months from now)

Drugs and Companies using VORAPAXAR SULFATE ingredient

Market Authorisation Date: 08 May, 2014

Treatment: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad)

Dosage: TABLET;ORAL

More Information on Dosage

ZONTIVITY family patents

Family Patents

List of large molecules

1. List of Cimzia large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7012135 NA NA
Feb, 2024

(a month ago)

2. List of Elelyso large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US8227230 NA NA
Feb, 2024

(30 days ago)

3. List of Aranesp large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7217689 NA NA
May, 2024

(a month from now)

4. List of Avastin large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US9795672 GENENTECH, INC. Treatment with anti-VEGF antibodies
May, 2024

(2 months from now)

Ingredients: BEVACIZUMAB

5. List of Adcetris large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7829531 NA Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
Jun, 2024

(2 months from now)

Ingredients: BRENTUXIMAB

6. List of Tysabri large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7759117 BIOGEN INC. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
Jun, 2024

(2 months from now)

US7157276 BIOGEN INC. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
Jun, 2024

(2 months from now)

Ingredients: NATALIZUMAB

7. List of Fasenra large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7718175 NA Method of modulating the activity of functional immune molecules to interleukin-5 receptor protein
Jul, 2024

(3 months from now)

Ingredients: BENRALIZUMAB

8. List of Simponi large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7691378 NA NA
Sep, 2024

(5 months from now)